Bioavailability/Bioequivalence Strategies for MPTs – Feasibility and Risks
January 2016
Click for full info +Bioavailability/Bioequivalence Strategies for MPTs – Feasibility and Risks
![]() | 26 January 2017 This live webinar focused on critical conversations around bioavailability and bioequivalence strategies for MPTs, including feasibility and risks. The webinar featured a presentation by Charles DiLiberti of Montclair Bioequivalence Services and a facilitated discussion with Laneta Dorflinger of FHI 360 and Joseph Romano of the IMPT. DiLiberti,C., Dorflinger, L., Romano, J. |
In this Webinar:
Product Type(s):MPTs
Topic(s):MPTs Risk